nach oben

Erschienen in:

20.05.2016 | Original Article

Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study

verfasst von: A. Ingels, M. Hew, F. Algaba, O. J. de Boer, R. J. A. van Moorselaar, S. Horenblas, P. Zondervan, J. J. M. C. H. de la Rosette, M. Pilar Laguna Pes

Erschienen in: World Journal of Urology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Clinical outcomes prognostic markers are awaited in clear-cell renal carcinoma (ccRCC) to improve patient-tailored management and to assess six different markers’ influence on clinical outcomes from ccRCC specimen and their incremental value combined with TNM staging.

Materials and methods

This is a retrospective, multicenter study. One hundred and forty-three patients with pT1b-pT3N0M0 ccRCC were included. Pathology specimens from surgeries were centrally reviewed, mounted on a tissue micro-array and stained with six markers: CAIX, c-MYC, Ki67, p53, vimentin and PTEN. Images were captured through an Ultra Fast Scanner. Tumor expression was measured with Image Pro Plus. Cytoplasmic markers (PTEN, CAIX, vimentin, c-MYC) were expressed as surface percentage of expression. Nuclear markers (Ki67, p53) were expressed as number of cells/mm². Clinical data and markers expression were compared with clinical outcomes. Each variable was included in the Cox proportional multivariate analyses if p < 0.10 on univariate analyses. Discrimination of the new marker was calculated with Harrell’s concordance index.

Results

At median follow-up of 63 months (IQR 35.0–91.8), on multivariate analysis, CAIX under-expression and vimentin over-expression were associated with worse survival (recurrence, specific and overall survival). A categorical marker CAIX-/Vimentin+ with cutoff points for CAIX and vimentin of 30 and 50 %, respectively, was designed. The new CAIX-/Vimentin+ marker presented a good concordance and comparable calibration to the reference model. Limitations are the retrospective design, the need for external validation and the large study period.

Conclusion

Using an automated technique of measurement, CAIX and vimentin are independent predictors of clinical outcomes in ccRCC.

Nur mit Berechtigung zugänglich

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924CrossRefPubMed

Rüdiger T, Höfler H, Kreipe H-H, Nizze H, Pfeifer U, Stein H et al (2002) Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 26(7):873–882CrossRefPubMed

Sobin LH, Wittekind Ch (eds) (2002) TNM classification of malignant tumors, UICC International Union Against Cancer, 6th edn. Wiley, NY, pp 193–195

Karakiewicz PI, Briganti A, Chun FK-H, Trinh Q-D, Perrotte P, Ficarra V et al (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol Off J Am Soc Clin Oncol 25(11):1316–1322CrossRef

Sobin L, Gospodarowitcz M, Wittekind Ch (eds) (2009) TNM classification of malignant tumors, UICC International Union Against Cancer, 7th edn. Wiley, NY, pp 255–257

Sakai I, Miyake H, Takenaka A, Fujisawa M (2009) Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU Int 104(7):942–946CrossRefPubMed

Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A et al (2014) Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU Int 113(4):668–673CrossRefPubMed

Tang S-W, Chang W-H, Su Y-C, Chen Y-C, Lai Y-H, Wu P-T et al (2009) MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett 273(1):35–43CrossRefPubMed

Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R et al (2005) p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173(3):725–728CrossRefPubMed

10.

Li G, Feng G, Gentil-Perret A, Genin C, Tostain J (2007) CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy. Clin Exp Metastasis 24(3):149–155CrossRefPubMed

11.

Bui MHT, Seligson D, Han K, Pantuck AJ, Dorey FJ, Huang Y et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res Off J Am Assoc Cancer Res 9(2):802–811

12.

Luong-Player A, Liu H, Wang HL, Lin F (2014) Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues. Am J Clin Pathol 141(2):219–225CrossRefPubMed

13.

Kim HL, Seligson D, Liu X, Janzen N, Bui MHT, Yu H et al (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 10(16):5464–5471CrossRef

14.

Sabo E, Miselevich I, Bejar J, Segenreich M, Wald M, Moskovitz B et al (1997) The role of vimentin expression in predicting the long-term outcome of patients with localized renal cell carcinoma. Br J Urol 80(6):864–868CrossRefPubMed

15.

Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T et al (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154(4):981–986CrossRefPubMedPubMedCentral

16.

Skinnider BF, Folpe AL, Hennigar RA, Lim SD, Cohen C, Tamboli P et al (2005) Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol 29(6):747–754CrossRefPubMed

17.

Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo Park C (2003) Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol 84(3):166–172CrossRefPubMed

18.

Wang C-J, Zhou Z-G, Holmqvist A, Zhang H, Li Y, Adell G et al (2009) Survivin expression quantified by Image Pro-Plus compared with visual assessment. Appl Immunohistochem Mol Morphol AIMM Off Publ Soc Appl Immunohistochem 17(6):530–535CrossRef

19.

Gu J, Liang Y, Qiao L, Li X, Li X, Lu Y et al (2013) Expression analysis of URI/RMP gene in endometrioid adenocarcinoma by tissue microarray immunohistochemistry. Int J Clin Exp Pathol 6(11):2396–2403PubMedPubMedCentral

20.

Zhang X, Wang H, Wang J (2013) Expression of HMGB1 and NF-κB p65 and its significance in non-small cell lung cancer. Contemp Oncol Pozn Pol 17(4):350–355

21.

Lu JG, Li Y, Li L, Kan X (2011) Overexpression of osteopontin and integrin αv in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis. J Cancer Res Clin Oncol 137(11):1613–1618CrossRefPubMed

22.

Shi H, Hayes M, Kirana C, Miller R, Keating J, Macartney-Coxson D et al (2012) TUFM is a potential new prognostic indicator for colorectal carcinoma. Pathology (Philadelphia) 44(6):506–512

23.

Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S et al (2012) Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 7(12):e51862CrossRefPubMedPubMedCentral

24.

Nguyen CT, Kattan MW (2011) How to tell if a new marker improves prediction. Eur Urol 60(2):226–228 (discussion 228–230) CrossRefPubMed

25.

Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G et al (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158(3):905–919CrossRefPubMedPubMedCentral

26.

Brewer CA, Liao SY, Wilczynski SP, Pastorekova S, Pastorek J, Zavada J et al (1996) A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol Oncol 63(3):337–344CrossRefPubMed

27.

Turner JR, Odze RD, Crum CP, Resnick MB (1997) MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum Pathol 28(6):740–744CrossRefPubMed

28.

Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastoreková S, Pastorek J et al (1998) Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153(1):279–285CrossRefPubMedPubMedCentral

29.

Stillebroer AB, Mulders PFA, Boerman OC, Oyen WJG, Oosterwijk E (2010) Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 58(1):75–83CrossRefPubMed

30.

Perlson E, Michaelevski I, Kowalsman N, Ben-Yaakov K, Shaked M, Seger R et al (2006) Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. J Mol Biol 364(5):938–944CrossRefPubMed

31.

Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T (2007) Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100(3):556–560CrossRefPubMed

32.

Patard J-J, Fergelot P, Karakiewicz PI, Klatte T, Trinh Q-D, Rioux-Leclercq N et al (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer J Int Cancer 123(2):395–400CrossRef

33.

Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB et al (2009) Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 18(3):894–900CrossRef

34.

True L, Feng Z (2005) Immunohistochemical validation of expression microarray results. J Mol Diagn 7(2):149–151CrossRefPubMedPubMedCentral

Titel: Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study
verfasst von: A. Ingels
M. Hew
F. Algaba
O. J. de Boer
R. J. A. van Moorselaar
S. Horenblas
P. Zondervan
J. J. M. C. H. de la Rosette
M. Pilar Laguna Pes
Publikationsdatum: 20.05.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 1/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1854-y

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy

American Confederation of Urology (CAU) experience in minimally invasive partial nephrectomy

Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer

Risk factors for recurrence in female urethral diverticulectomy: a retrospective study of 66 patients

Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomy

Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie